No Data
Express News | Organovo Announces Close of the Sale of Fxr Program to Eli Lilly and Company
Eli Lilly Could See Higher Q1 Sales for Zepbound, UBS Says
Press Release: Organovo Announces Close of the Sale of FXR Program to Eli Lilly and Company
Schneider Electric announces an investment of 0.7 billion USD to strengthen its Business in the USA and address tariff threats by enhancing AI Energy Infrastructure.
French Electrical Equipment manufacturer Schneider Electric SE announced on Tuesday that it plans to invest over 0.7 billion USD in its USA Business over the next two years to address potential tariff threats affecting its business. The company stated that this investment, which will continue until 2027, will focus on strengthening its Energy infrastructure in the USA, providing power support for AI development, boosting domestic manufacturing, and enhancing energy security. Since the inauguration of USA President Trump, tariffs have been imposed on a variety of Commodities ranging from Aluminum and Steel to Pharmaceuticals and Semiconductors.
Proposed Medicaid Cuts Would Devastate Local Economies: Report -- Barrons.com
Lilly Announces Details of Presentations at 2025 American Association for Cancer Research (AACR) Annual Meeting
![[undefined]](https://static.moomoo.com/nnq/emoji/static/image/default/default-black.png?imageMogr2/thumbnail/36x36 "undefined"){kind=small}
Junius Falcon : Buy when back to 720 or even 650. EPS up 70% YoY by 2025, will end up P/E 30+y, but only little growth in 2026, so it would go sideway in mid term.
LLY is diversified drugs, it is safer. NVO needs new drugs than weight loss. If they get out competed in that they are done. Its current EPS growth does support its current P/E